JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $14 from $10 and keeps an Overweight rating on the shares following the Q2 report. The firm believes momentum in the minimal residual disease business positions Adaptive for a strong back half of the year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies Reports Strong Q2 2025 Growth
- Adaptive Biotechnologies: Strong Financial Performance and Strategic Initiatives Drive Optimistic Outlook
- Adaptive Biotechnologies reports Q2 EPS (17c), consensus (24c)
- COIN, BMNR, RBLX: Cathie Wood Buys Over $54M of Crypto Stocks, Dumps Roblox Stake
- Cathie Wood Buys $69M Worth of Figma Stock on Blockbuster IPO Debut